Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

The phase 3 OASIS 4 trial was a 52-week randomized study assessing the safety and efficacy of elinzanetant, a dual NK1/NK3 receptor antagonist, in women aged 18 to 70 who were receiving treatment for—or were at high risk of—HR+ breast cancer and who were experiencing at least 35 moderate-to-severe vasomotor symptoms per week related to adjuvant endocrine therapy. The investigators found that elinzanetant was efficacious and well tolerated for the treatment of vasomotor symptoms associated with adjuvant endocrine therapy.